Tumor angiogenesis revisited: Regulators and clinical implications

Area of Science:

• Oncology
• Vascular Biology
• Medical Research

Background:

• The hypothesis that solid tumor growth requires angiogenesis was proposed in 1971.
• The development of antiangiogenic agents, such as bevacizumab targeting vascular endothelial growth factor, began with the first approval in 2004 for metastatic colorectal cancer.
• Despite initial high expectations, the clinical efficacy of antiangiogenic therapy in malignant diseases has not fully materialized, prompting a need to revisit its regulatory and clinical implications.

Purpose of the Study:

• To review recent advancements in understanding angiogenesis mediators and pathways.
• To discuss emerging concepts in angiogenesis research over the past decade.
• To analyze tumor resistance and toxicity associated with current antiangiogenic treatments and explore novel therapeutic targets for neovascular diseases.

Main Methods:

• Literature review of recent studies on angiogenesis.
• Analysis of new concepts and paradigms in blood vessel formation.
• Evaluation of clinical data on antiangiogenic therapies, including resistance and toxicity.

Main Results:

• Identification of newly discovered angiogenesis mediators and pathways.
• Emergence of new concepts challenging original paradigms of angiogenesis.
• Documentation of tumor resistance and adverse effects associated with existing antiangiogenic treatments.

Conclusions:

• Current antiangiogenic therapies face limitations in clinical application for cancer treatment.
• A deeper understanding of angiogenesis mechanisms is required to overcome resistance and toxicity.
• New therapeutic targets and strategies are needed for both malignant and nonmalignant neovascular diseases.